Experts in Dengue Control Form New Alliance to Bridge Vaccine and Vector Approaches and Expand Efforts to Zika and other Aedes-Transmitted Diseases

Mexico City, Mexico – August 31, 2016 – Today, four leading institutions at the forefront of dengue prevention and control—the International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) of the Johns Hopkins University, the Partnership for Dengue Control Foundation (PDC) and the Sabin Vaccine Institute—announced a new global alliance to integrate approaches to fight dengue and other Aedes-transmitted diseases under one strategic umbrella. Named the Global Dengue and Aedes-transmitted Diseases Consortium (GDAC), this new partnership will expand its expertise in dengue to other Aedes-transmitted diseases including Zika, chikungunya and yellow fever, responding to the urgent need for coordination in the currently fragmented efforts to control the diseases transmitted by one of the world's most dangerous animals—the Aedes mosquito.

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.

Dengue Vaccine Initiative awarded grant from Germany for development of new dengue vaccines in Brazil and Vietnam

SEOUL, SOUTH KOREA - The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.